Shedir Pharma Srl Unipersonale
MIL:SHE
Shedir Pharma Srl Unipersonale
MIL:SHE
Price:
4.88
EUR
Market Cap:
€55.8m
Balance Sheet
Balance Sheet Decomposition
Shedir Pharma Srl Unipersonale
Shedir Pharma Srl Unipersonale
Balance Sheet Decomposition is not available for
Shedir Pharma Srl Unipersonale
Shedir Pharma Srl Unipersonale
Balance Sheet
Shedir Pharma Srl Unipersonale
Shedir Pharma Srl Unipersonale
Currency: EUR
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
6
|
3
|
6
|
16
|
19
|
16
|
1
|
|
| Cash |
0
|
3
|
6
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
6
|
0
|
0
|
16
|
19
|
16
|
1
|
|
| Total Receivables |
8
|
14
|
14
|
12
|
12
|
16
|
18
|
|
| Accounts Receivables |
7
|
12
|
11
|
10
|
10
|
13
|
14
|
|
| Other Receivables |
0
|
2
|
3
|
2
|
2
|
3
|
4
|
|
| Inventory |
8
|
14
|
14
|
12
|
9
|
12
|
18
|
|
| Other Current Assets |
2
|
0
|
0
|
0
|
0
|
0
|
6
|
|
| Total Current Assets |
24
|
31
|
35
|
41
|
41
|
44
|
42
|
|
| PP&E Net |
12
|
13
|
7
|
6
|
6
|
5
|
8
|
|
| PP&E Gross |
0
|
13
|
7
|
6
|
6
|
5
|
8
|
|
| Accumulated Depreciation |
0
|
2
|
16
|
5
|
7
|
8
|
10
|
|
| Intangible Assets |
4
|
4
|
5
|
5
|
5
|
7
|
6
|
|
| Note Receivable |
0
|
11
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
10
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Total Assets |
50
N/A
|
60
+20%
|
48
-20%
|
53
+10%
|
53
0%
|
57
+8%
|
56
-1%
|
|
| Liabilities | ||||||||
| Accounts Payable |
9
|
8
|
6
|
7
|
9
|
11
|
9
|
|
| Accrued Liabilities |
0
|
3
|
2
|
1
|
1
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
7
|
8
|
8
|
4
|
3
|
4
|
4
|
|
| Other Current Liabilities |
2
|
3
|
1
|
1
|
1
|
1
|
1
|
|
| Total Current Liabilities |
18
|
22
|
17
|
13
|
14
|
16
|
14
|
|
| Long-Term Debt |
10
|
11
|
7
|
12
|
9
|
7
|
5
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Liabilities |
30
N/A
|
34
+13%
|
25
-25%
|
26
+3%
|
24
-6%
|
24
-2%
|
20
-16%
|
|
| Equity | ||||||||
| Common Stock |
1
|
1
|
2
|
2
|
2
|
2
|
2
|
|
| Retained Earnings |
16
|
22
|
12
|
16
|
18
|
22
|
26
|
|
| Additional Paid In Capital |
4
|
4
|
9
|
9
|
9
|
9
|
9
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
20
N/A
|
26
+29%
|
23
-15%
|
27
+18%
|
28
+6%
|
33
+16%
|
36
+10%
|
|
| Total Liabilities & Equity |
50
N/A
|
60
+20%
|
48
-20%
|
53
+10%
|
53
0%
|
57
+8%
|
56
-1%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
11
|
11
|
11
|
11
|
11
|
11
|
11
|
|
Switch to:
Switch to:
See Also
Discover More
